Trinity Biotech plc Asset Resilience Ratio
Trinity Biotech plc asset resilience ratio. Trinity Biotech plc (TRIB) has an Asset Resilience Ratio of 29.53% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Trinity Biotech plc (TRIB) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Trinity Biotech plc (1997–2020)
Asset resilience ratio of Trinity Biotech plc from 1997 to 2020. This chart shows how Trinity Biotech plc's Asset Resilience Ratio has changed over time. Read how much debt does Trinity Biotech plc carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Trinity Biotech plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Trinity Biotech plc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $18.78 Million | 29.53% |
| Total Liquid Assets | $18.78 Million | 29.53% |
Asset Resilience Insights
- Very High Liquidity: Trinity Biotech plc maintains exceptional liquid asset reserves at 29.53% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Trinity Biotech plc Industry Peers by Asset Resilience Ratio
Compare Trinity Biotech plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Applied BioCode
TW:6598 |
Medical Devices | 9.75% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Radiant Innovation
TWO:3373 |
Medical Devices | 0.82% |
|
Impedimed Ltd
AU:IPD |
Medical Devices | 46.15% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
Trinity Biotech plc Asset Resilience Ratio by Year (1997–2020)
Trinity Biotech plc asset resilience ratio by year from 1997 to 2020. The table below shows the annual Asset Resilience Ratio data for Trinity Biotech plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 0.00% | $0.00 | $130.40 Million | -- |
| 2019-12-31 | 0.89% | $1.17 Million | $131.07 Million | -14.60pp |
| 2018-12-31 | 15.49% | $23.42 Million | $151.24 Million | -2.19pp |
| 2017-12-31 | 17.67% | $34.04 Million | $192.62 Million | -8.70pp |
| 2015-12-31 | 26.37% | $94.66 Million | $358.96 Million | +25.60pp |
| 2014-12-31 | 0.77% | $1.88 Million | $242.84 Million | -5.09pp |
| 2013-12-31 | 5.86% | $13.28 Million | $226.49 Million | -26.30pp |
| 2012-12-31 | 32.17% | $63.50 Million | $197.41 Million | -7.43pp |
| 2011-12-31 | 39.59% | $67.90 Million | $171.50 Million | +5.03pp |
| 2010-12-31 | 34.56% | $55.60 Million | $160.87 Million | +33.50pp |
| 2009-12-31 | 1.06% | $1.40 Million | $132.44 Million | -0.49pp |
| 2008-12-31 | 1.54% | $2.00 Million | $129.51 Million | -0.54pp |
| 2007-12-31 | 2.08% | $4.50 Million | $215.98 Million | -4.14pp |
| 2006-12-31 | 6.22% | $15.50 Million | $249.13 Million | +3.53pp |
| 2005-12-31 | 2.69% | $4.96 Million | $184.60 Million | +2.47pp |
| 1998-12-31 | 0.22% | $100.00K | $45.00 Million | -5.47pp |
| 1997-12-31 | 5.69% | $1.40 Million | $24.60 Million | -- |
About Trinity Biotech plc
Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually tr… Read more